Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.

@article{Shimada2003SecondlineCW,
  title={Second-line chemotherapy with combined irinotecan and low-dose cisplatin for patients with metastatic gastric carcinoma resistant to 5-fluorouracil.},
  author={Shinya Shimada and Yasushi Yagi and Masafumi Kuramoto and Norimitsu Aoki and Michio Ogawa},
  journal={Oncology reports},
  year={2003},
  volume={10 3},
  pages={687-91}
}
Although 5-fluorouracil (5-FU) is still the mainstay of systemic treatment for patients with metastatic gastric cancer, many patients do not show satisfactory response to this drug. We treated patients with metastatic gastric cancer resistant to 5-FU with a combination of irinotecan hydrochloride (I) and low-dose cisplatin (P). Twenty-one consecutive patients with advanced metastatic gastric cancer and performance status of 0-2, who had received prior chemotherapy with S-1, but had nonetheless… CONTINUE READING
9 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-9 of 9 extracted citations

Similar Papers

Loading similar papers…